Intra-tumor heterogeneity is also implied by the ASCO/CAP criterion for a tumor to be considered HER2-positive, which requires only 10% of tumor cells with complete and intense membrane staining, and by the relationship between the heterogeneity of HER2 staining and clinical outcomes [33, 34]. The gene discussed is ERBB2; the disease is neoplasm.